Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome

Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL

Published:2020-10-08 Issue:15 Volume:136 Page:1786-1789
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Saini Neeraj¹,Marin David¹,Ledesma Celina¹,Delgado Ruby¹,Rondon Gabriela¹,Popat Uday R.¹^ORCID,Bashir Qaiser¹^ORCID,Hosing Chitra M.¹,Nieto Yago¹^ORCID,Alousi Amin M.¹,Qazilbash Muzaffar H.¹,Ciurea Stefan¹^ORCID,Shpall Elizabeth¹,Khouri Issa¹,Kantarjian Hagop²^ORCID,Jabbour Elias²,Ravandi Farhad²,Champlin Richard E.¹^ORCID,Kebriaei Partow¹

Affiliation:

1. Department of Stem Cell Transplantation and Cellular Therapy and

2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract

How to best use tyrosine kinase inhibitors (TKIs) of BCR-ABL after allogeneic stem cell transplantation for Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) is unknown but will almost certainly not be addressed by a definitive randomized trial. Saini and colleagues provide a large body of observational data to reinforce earlier circumstantial evidence favoring prophylactic use of TKIs for at least 2 years posttransplant.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/136/15/1786/1760629/bloodbld2019004685.pdf

Reference14 articles.

1. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia;Abou Dalle;Curr Treat Options Oncol,2019

2. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Ph+ ALL, A Systematic Review;Warraich;Biol Blood Marrow Transplant,2020

3. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation;Giebel;Cancer,2016

4. Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: is it imperative in the tyrosine kinase inhibitor era?;Litzow;Best Pract Res Clin Haematol,2018

5. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia;Carpenter;Blood,2007

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Prévention de la rechute des leucémies aiguës et syndromes myélodysplasiques en post-allogreffe : stratégies prophylactique et préemptive (SFGM-TC);Bulletin du Cancer;2024-09

3. Comparison of atrial fibrillation prevalence and in-hospital cardiovascular outcomes between patients undergoing allogeneic versus autologous hematopoietic stem cell transplantation: insights from the national inpatient sample;Scientific Reports;2024-07-22

4. How I use next-generation sequencing–MRD to plan approach and prevent relapse after HCT for children and adults with ALL;Blood;2024-07-18

5. Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions;Leukemia;2024-06-20